Anti-arthritis activity of cationic materials

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 7, 2010, Pages 2015-2024

  Dong, Lei ^a   Xia, Suhua ^a   Chen, Huan ^a   Chen, Jiangning ^a   Zhang, Junfeng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Arthritis; Cationic material; IFN ; IL 12

Indexed keywords

ANTIINFLAMMATORY AGENT; CATION; CYTOKINE;

ANIMAL; ARTHRITIS; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; FEMALE; METABOLISM; MOUSE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; CATIONS; CYTOKINES; FEMALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; MUS; RATTUS;

EID: 77955801910     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00806.x     Document Type: Article

References (30)

1. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007, 120:936-9.
2. Bingham CO, Miner MM. Treatment, management, and monitoring of established rheumatoid arthritis. J Fam Pract 2007, 56:S1-7.
3. Sigidin IA, Lukina GV. State-of-the-art biological therapy of rheumatoid arthritis. Vestn Ross Akad Med Nauk. 2008, 6:19-24.
4. Lutt JR, Deodhar A. Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNF alpha antagonists. Drugs. 2008, 68:591-606.
5. Vermeire K, Heremans H, Vandeputte M. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997, 158:5507-13.
6. Guedez YB, Whittington KB, Clayton JL. Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum. 2001, 44:2413-24.
7. Manoury-Schwartz B, Chiocchia G, Bessis N. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol. 1997, 158:5501-6.
8. Wu HJ, Sawaya H, Binstadt B. Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. J Exp Med. 2007, 204:1911-22.
9. Williams AS, Richards PJ, Thomas E. Interferon-gamma protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis Rheum. 2007, 56:2244-54.
10. Irmler IM, Gajda M, Bräuer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol. 2007, 179:6228-36.
11. Veys EM, Menkes CJ, Emery P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1997, 40:62-8.
12. Kim SW, Ogawa T, Tabata Y, Nishimura I. Efficacy and cytotoxicity of cationic-agent-mediated nonviral gene transfer into osteoblasts. J Biomed Mater Res A. 2004, 71:308-15.
13. Snyder SL, Sobocinski PZ. An improved 2,4,6-trinitrobenzensulfonic acid method for the determination of mines. Anal Biochem. 1975, 64:284-8.
14. Hermanson GT. Bioconjugate techniques 1996, New York, Academic Press
15. Jun HS, Yoon CS, Zbytnuik L. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med. 1999, 189:347-58.
16. Taurog JD, Kerwar SS, McReynolds RA. Synergy between adjuvant arthritis and collagen-induced arthritis in rats. J Exp Med. 1985, 162:962-78.
17. Richards PJ, Williams BD, Williams AS. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology. 2001, 40:978-87.
18. Weiss A, Fitch FW. Macrophages suppress CTL generation in rat mixed leukocyte cultures. J Immunol. 1977, 119:510-6.
19. Luten J, van Nostrum CF, De Smedt SC. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release. 2008, 126:97-110.
20. Azzam T, Domb AJ. Current developments in gene transfection agents. Curr Drug Deliv. 2004, 1:165-93.
21. Mario CF, Nigel CP. Anti-inflammatory activity of cationic lipids. Br J Pharmacol. 1997, 122:551-7.
22. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release. 2004, 94:1-14.
23. Brown MD, Schätzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm. 2001, 229:1-21.
24. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003, 3:133-46.
25. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005, 5:606-16.
26. Jin MS, Lee JO. Structures of the toll-like receptor family and its ligand complexes. Immunity. 2008, 29:182-91.
27. Kotenko SI, Lisunkin II. Use of polymers in medicine. Farm Zh. 1971, 26:17-24.
28. Vicennati P, Giuliano A, Ortaggi G. Polyethylenimine in medicinal chemistry. Curr Med Chem. 2008, 15:2826-39.
29. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immuno. 2001, 2:37-45.
30. Lungwitz U, Breunig M, Blunk T. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005, 60:247-66.